This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tacke, J. Articles by Jauch, K.-W. Search for Related Content PubMed PubMed Citation Articles by Tacke, J. Articles by Jauch, K.-W. Social Bookmarking                         What's this?

Long-Term Risk of Gastrointestinal Tumor Recurrence After Postoperative Treatment with Recombinant Human Growth Hormone

Department of Surgery, Dortmund Academic Hospital, Dortmund, Germany, Department of Plastic and Reconstructive Surgery, Marienhospital, Stuttgart, Germany

Ulrich Bolder, MD

Department of Surgery, Dortmund Academic Hospital, Dortmund, Germany, , ulrich_bolder{at}yahoo.com, Department of Surgery, University of Regensburg, Regensburg, Germany

Armin Herrmann, MD

Department of Surgery, Clinic-Grosshadern, Ludwig-Maximillians-University, Munich, Germany, Department of Surgery, University of Regensburg, Regensburg, Germany

Gerd Berger, MD

Department of Surgery, Free University Berlin, Benjamin Franklin University Hospital, Berlin, Germany

Karl-Walter Jauch, MD

Department of Surgery, Clinic-Grosshadern, Ludwig-Maximillians-University, Munich, Germany

Background: Recombinant human growth hormone (rhGH) promotes protein synthesis, accelerates wound healing, and maintains immune function in the catabolic state. It has also been claimed that rhGH may promote the activation of residual tumor cells, and therefore, increases the risk of tumor recurrence. This study aimed to investigate whether postoperative administration of rhGH increases the long-term risk of tumor recurrences in patients undergoing major gastrointestinal surgery for malignancy. Methods: Patients (n =104) received three different doses of rhGH (0.075 IU/kg, 0.150 IU/kg, and 0.300 IU/kg) during 5 postoperative days in a placebo-controlled trial. Follow-up was performed for 56-70 months after radical tumor resection. Mean survival period and relapse-free survival were compared with the control group. Results: Complete data were available for 75 patients. Thirty-five percent (n = 20) of all patients treated with rhGH showed tumor recurrences in comparison to 44% (n = 8) of patients given placebo. Mean survival period for rhGH-treated patients was 46 months (median 59 months); in controls, 42 months (median 58 months). The length of relapse-free survival tended to be longer in rhGH-treated patients (2-47 months; median, 21 months) compared with the patients who were given placebo (2-18 months; median, 13 months). Conclusions: The results demonstrate no evidence for an increased risk of tumor recurrence after rhGH treatment for a short period of time after removal of a gastrointestinal adenocarcinoma. Therefore, the positive metabolic effects of rhGH application can be used safely in the treatment of the postoperative catabolic state in the patient groups investigated. (Journal of Parenteral and Enteral Nutrition 24:140-144, 2000)

Journal of Parenteral and Enteral Nutrition, Vol. 24, No. 3, 140-144 (2000)
DOI: 10.1177/0148607100024003140


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Cao, S.-M. Luo, L. Liang, and J. Lai Effects of Parenteral Nutrition Without and With Growth Hormone on Growth Hormone/Insulin-Like Growth Factor-1 Axis After Hepatectomy in Hepatocellular Carcinoma With Liver Cirrhosis JPEN J Parenter Enteral Nutr, November 1, 2007; 31(6): 496 - 501. [Abstract] [Full Text] [PDF]

				C. Dalle and V. Claude Growth Hormone for "Antiaging" JAMA, February 22, 2006; 295(8): 889 - 889. [Full Text] [PDF]